Ocular Therapeutix (OCUL) On Phase 3 AMD Win And Why The Valuation Debate Persists
How Investors Are Reacting To Ocular Therapeutix (OCUL) Phase 3 Wet AMD Success
Ocular Therapeutix (OCUL) reports earnings tomorrow: what to expect
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $28
Ocular Therapeutix Inc (OCUL) Q3 2026 Earnings Call Highlights: Landmark Phase 3 Wins, NDA on ...
Ocular Therapeutix, Inc. Q3 2026 Earnings Call Summary
Ocular Tx (OCUL) Q3 2026 Earnings Call Transcript
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call
Ocular Therapeutix falls on third quarter earnings miss
Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript
Ocular Therapeutix: Q3 Earnings Snapshot
Ocular Therapeutix (NASDAQ:OCUL) reports sales below analyst estimates in Q3 2026 earnings, stock drops
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix Q3 2026 Earnings Call Transcript
Ocular Therapeutix Q3 EPS $(0.42) Misses $(0.36) Estimate, Sales $12.874M Miss $14.339M Estimate
Is Ocular Therapeutix (OCUL) Overvalued Given Its Current Sales Base?
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.